Mycobacterium abscessus is a multi-drug resistant species of non-tuberculous mycobacteria (NTM) that is increasingly emerging as a major threat to people with inflammatory lung diseases, such as cystic fibrosis (CF) [[1], [2], [3]]. Despite increased awareness of the issues faced by M. abscessus and recent publications of NTM-pulmonary disease (NTM-PD) treatment guidelines for people with CF (pwCF) in 2016 [4] and the ATS/ERS/ESCMID/IDSA guidelines in 2020 [5], the optimal treatment regimen for M. abscessus remains unclear and global treatment outcomes remain poor. There is hope that the advent of highly effective cystic fibrosis transmembrane regulator (CFTR) modulators may have the potential to reduce the rate of NTM acquisition by pwCF. Certainly, there are anecdotal case reports of pwCF with previously intractable NTM-PD caused by M. abscessus showing a remarkable improvement including, in some cases, eradication, following commencement of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI) [6]. However, the current literature describing the treatment outcomes for M. abscessus in pwCF, either pre- or post-modulator therapy remains limited. Despite the positive changes in the landscape facing CF, M. abscessus continues to be a source of significant morbidity and mortality.